Carewell Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 30 Year, 24 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.60 M
as on 19-12-2024
- Revenue 24.05%
(FY 2022)
- Profit 42.41%
(FY 2022)
- Ebitda 44.24%
(FY 2022)
- Net Worth 18.04%
(FY 2022)
- Total Assets 18.52%
(FY 2022)
About Carewell Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.60 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rosy Jain and Rakesh Jain serve as directors at the Company.
- CIN/LLPIN
U74899DL1994PTC063026
- Company No.
063026
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 1994
- Date of AGM
21 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Carewell Biotech Private Limited offer?
Carewell Biotech Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, IVDs & Analyzers, Calibration Services, Centrifuge Calibration, Electrolyte Analyzer, Clinical Reagents, Hematology Analyzers, Diatron Hematology Analyzers.
Who are the key members and board of directors at Carewell Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Jain  | Managing Director | 30-Nov-1994 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rosy Jain | Director | 01-Apr-1996 | Current |
Financial Performance of Carewell Biotech.
Carewell Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.05% increase. The company also saw a substantial improvement in profitability, with a 42.41% increase in profit. The company's net worth Soared by an impressive increase of 18.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carewell Biotech?
In 2019, Carewell Biotech had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 09 Dec 2005 | ₹0.60 M | Satisfied |
How Many Employees Work at Carewell Biotech?
Unlock and access historical data on people associated with Carewell Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carewell Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carewell Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
